• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>TheraSense

TheraSense

  1. Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma

    Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.